AXIM
Axim Biotechnologies, Inc.Company with tickers: AXIM
CIK
1514946
CUSIP
05463V100
Shares Outstanding
340,456,626
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $17,479 | USD | 2024-06-30 | 10-Q | 2024-08-19 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | $15,735 | USD | 2024-06-30 | 10-Q | 2024-08-19 |
| Operating Expenses | $585,176 | USD | 2024-06-30 | 10-Q | 2024-08-19 |
| Research & Development | $4,063 | USD | 2024-06-30 | 10-Q | 2024-08-19 |
| Operating Income | $-569,441 | USD | 2024-06-30 | 10-Q | 2024-08-19 |
| Net Income | $-2,269,815 | USD | 2024-06-30 | 10-Q | 2024-08-19 |
| EPS (Basic) | $-0.01 | USD/shares | 2024-06-30 | 10-Q | 2024-08-19 |
| EPS (Diluted) | $-0.01 | USD/shares | 2024-06-30 | 10-Q | 2024-08-19 |